Sera Prognostics Inc Cl A SERA

$2.09 +0.05 (2.45%)

Valuation

Market cap
82,448,000
Revenue TTM
$80,000
Net income TTM
$-31,930,000
PE ratio
0.00
Forward PE
—
Profit margin
-39,912.50%
Debt to equity
0.00

Trading

Volume
21,800
Avg volume
27,236
Day's range
$2.04 – $2.15
Shares out
39,449,000
Stochastic %K
45%
Beta
1.06
Analysts
Strong Sell
Price target
$5.50

Price

Company profile

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based bi...

Show more

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Industry
Medical Devices
Sector
Healthcare
Phone
801 990 0520
Website
https://www.sera.com
Address
2749 East Parleys Way, Suite 200, Salt Lake City, United States

Latest news

Stocktwits

Jimbob3016 Aug 25, 2:16 PM
$CBAT just secured a 96 million $ order $SERA great news!!!
0 replies
BioTechHealthX Aug 23, 3:58 PM
$CLPT $MASS $OSUR $PDEX $SERA Discover 5 high-potential small-cap medical stocks ranked by revenue growth, commercial traction, financial strength, catalysts, valuation, and overall investment risk. https://biotechhealthx.com/biotech-news/top-10-small-cap-medical-stocks-to-buy-before-august-2026-ends/
0 replies
martyn78 Aug 15, 3:36 AM
$SERA could see this getting some momentum
0 replies
StocktwitsEarnings Aug 12, 8:15 PM
$SERA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.18 down -12.50% YoY • Reported revenue of $0.03M up 76.47% YoY
0 replies
Wes_g Jul 22, 2:39 AM
$SERA Core Value Drivers: Demonstrated healthcare cost savings from the PreTRM® test should support broader reimbursement coverage by commercial and government payers, reducing barriers to adoption and driving test volume growth. Strong clinical outcomes, including the ability to identify pregnancies at risk of preterm birth and enable earlier intervention, should increase physician confidence, support broader payer reimbursement, and accelerate adoption. Inclusion of the PreTRM® test in professional pregnancy care guidelines would establish it as part of the standard of care for appropriate patient populations, significantly expanding its addressable market and long-term adoption. Leveraging SERA's proprietary biomarker platform to develop additional maternal health diagnostics could increase the company's total addressable market and improve long-term growth prospects.
0 replies
BioTuesdays Jul 10, 7:39 PM
$SERA has announced publication of a new subgroup analysis from the PRIME trial demonstrating that its PreTRM Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions. https://biotuesdays.com/2026/07/10/analysis-shows-22-cut-in-nicu-admissions-in-first-time-pregnancies-with-seras-pretrm/
0 replies
ctenidae Jul 10, 1:52 AM
$SERA https://www.sera.com/pregnancy-related-concerns/newsroom/prime-subgroup-analysis-demonstrates-22-reduction-in-nicu-admissions-in-first-time-pregnancies-using-pretrm-test-guided-care/ 22% reduction in NICU admissions. 2x decrease in NICU admissions for sPTB babies. Listen up, Illinois- this is good.
0 replies
ctenidae Jun 1, 12:23 PM
$SERA Illinois just passed new legislation mandating Sera' test: Page 390: Sec. 5-54. Coverage for proteomic blood tests. (a) The medical assistance program shall provide coverage and reimbursement for a prescribed proteomic blood test, with clinical trial proof of improved infant outcomes published in peer-reviewed journals, that identifies and quantifies the risk of preterm birth for an individual pregnancy https://ilga.gov/documents/legislation/104/SB/PDF/10400SB3365ham001.pdf
1 replies